Researchers uncover the placenta distinguishes between antibodies and albumin, allowing for the design of long-acting biologic medicines with reduced fetal exposure. Fusion of IgG antibodies to albumin inhibits transport across the placenta, enabling the development of safer treatments during pregnancy.
A new study reveals that increasing NAD⁺ levels corrects RNA splicing mistakes, improving brain function and restoring memory in animal models of Alzheimer's disease. The researchers discovered a previously unidentified pathway involving the protein EVA1C, which plays a crucial role in correcting tau-related neuronal damage.
Researchers designed long-acting human albumin-fused FIX variants with unique pharmacokinetic properties, including extended plasma half-lives and enhanced extravascular distribution. The findings endorse the use of engineered albumin-fused FIX variants as personalized therapy options for hemophilia B.
Researchers highlight NAD+ supplements as potential key to healthier ageing and disease prevention, but call for larger studies. Early trials report improvements in memory, movement, and metabolism.